Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQT study of intravenous amisulpride (APD421)
NCT02661594Phase 1Completed
- Sponsor
- Acacia Pharma Group Plc
- Start
- Nov 2013
- Primary completion
- Mar 2014
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of amisulpride in postoperative nausea and vomiting (PONV) (4 arms), sponsored by Acacia Pharma Group Plc. Primary endpoint: Maximal Mean Placebo-Corrected Change from Baseline of QTcF at 24 hours. Started Nov 2013; status: completed.
02
Drugs
amisulpride
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT02661594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661594.